CLASS II Drug recall · Reported 8 Feb 2023 · FDA Enforcement Report
Conzerol zero molluscum contagiosum recalled by Discovery Pharma
Discovery Pharma is recalling Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, distributed in California, Florida, Washington. The recall was initiated on 9 Nov 2022 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0261-2023
- FDA event ID
- 91559
- Recalling firm
- Discovery Pharma, Oviedo, FL
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 9 Nov 2022
- FDA classified
- 1 Feb 2023
- Reported
- 8 Feb 2023
- Type
- Voluntary: Firm initiated
- Customers notified by
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- Reason category
- Manufacturing (CGMP) Deviations
- Drug class
- Creams, Ointments & Gels
Timeline
| 9 Nov 2022 | Recall initiated by company | |
| 1 Feb 2023 | Classified by FDA | +84 days |
| 8 Feb 2023 | Published in enforcement report | +7 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
CGMP deviations
Product as listed by the FDA
Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland
Where it was distributed
CA, FL, WA
Questions about this recall
Why was it recalled?
CGMP deviations
Which lots are affected?
Lots: 22123 Exp. 01/2024; 21732 Exp. 07/2023
Where was it sold?
CA, FL, WA
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.